General Information of Drug (ID: DMAYD7O)

Drug Name
IT-141 Drug Info
Cross-matching ID
PubChem CID
104842
TTD Drug ID
D0K6QU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.71 0.00e+0 63/73 (86.3%) CDKN1A;SESN1;DDB2;...
Oxidative phosphorylation 2.27 0.00e+0 93/133 (69.92%) NDUFB1;COX5A;ATP5PF;...
Epstein-Barr virus infection 2.18 0.00e+0 189/202 (93.56%) CDKN1A;DDB2;GADD45A;...
Type I diabetes mellitus 2.12 0.00e+0 38/43 (88.37%) HLA-B;FAS;HLA-DQA1;...
Autoimmune thyroid disease 2.09 0.00e+0 46/53 (86.79%) HLA-B;FAS;HLA-DQA1;...
Allograft rejection 2.08 0.00e+0 32/38 (84.21%) HLA-B;FAS;HLA-DQA1;...
Graft-versus-host disease 2.06 0.00e+0 32/42 (76.19%) HLA-B;FAS;HLA-DQA1;...
Influenza A 1.97 1.14e-3 156/172 (90.7%) TNFRSF10B;NFKBIA;FAS;...
Viral protein interaction with cytokine and cytokine re... 1.93 1.02e-3 84/100 (84%) TNFRSF10B;CXCL14;CXCL10;...
Thyroid cancer 1.90 2.75e-3 36/37 (97.3%) CDKN1A;DDB2;GADD45A;...
Cytosolic DNA-sensing pathway 1.89 2.50e-3 52/63 (82.54%) NFKBIA;POLR2L;CXCL10;...
Herpes simplex virus 1 infection 1.84 6.10e-3 165/498 (33.13%) NFKBIA;HLA-B;FAS;...
Basal cell carcinoma 1.84 7.04e-3 41/63 (65.08%) CDKN1A;DDB2;GADD45A;...
Measles 1.79 1.11e-2 133/139 (95.68%) NFKBIA;FAS;BCL2L1;...
Viral myocarditis 1.78 1.10e-2 53/60 (88.33%) CXADR;HLA-B;HLA-DQA1;...
Non-alcoholic fatty liver disease 1.76 1.32e-2 126/155 (81.29%) FAS;NDUFB1;BAX;...
Parkinson disease 1.76 1.35e-2 176/249 (70.68%) PPIF;BCL2L1;NDUFB1;...
Nucleotide excision repair 1.75 1.27e-2 40/47 (85.11%) DDB2;PCNA;LIG1;...
Small cell lung cancer 1.75 1.25e-2 90/92 (97.83%) CDKN1A;DDB2;GADD45A;...
Chronic myeloid leukemia 1.74 1.33e-2 72/76 (94.74%) CDKN1A;DDB2;GADD45A;...
NF-kappa B signaling pathway 1.70 2.09e-2 90/104 (86.54%) GADD45A;NFKBIA;RELB;...
Staphylococcus aureus infection 1.69 2.16e-2 72/95 (75.79%) KRT17;KRT14;KRT16;...
Glioma 1.69 2.15e-2 67/75 (89.33%) CDKN1A;DDB2;GADD45A;...
Hepatitis C 1.68 2.25e-2 139/157 (88.54%) CDKN1A;NFKBIA;FAS;...
Ribosome 1.68 2.20e-2 113/158 (71.52%) RPS27L;MRPL34;MRPS2;...
Pancreatic cancer 1.67 2.32e-2 75/76 (98.68%) CDKN1A;DDB2;GADD45A;...
Toll-like receptor signaling pathway 1.66 2.27e-2 94/104 (90.38%) NFKBIA;CXCL10;CASP8;...
Inflammatory bowel disease 1.64 2.68e-2 58/65 (89.23%) HLA-DQA1;MAF;IL2RG;...
Apoptosis 1.64 2.59e-2 126/168 (75%) PMAIP1;GADD45A;TNFRSF10B;...
DNA replication 1.63 2.90e-2 34/36 (94.44%) PCNA;FEN1;LIG1;...
Salivary secretion -1.61 3.83e-2 76/93 (81.72%) CALML5;GUCY1B1;CHRM3;...
Sphingolipid signaling pathway -1.62 3.64e-2 106/119 (89.08%) ADORA1;NSMAF;ABCC1;...
Thyroid hormone synthesis -1.62 3.73e-2 66/75 (88%) CREB3L1;ATP1B3;HSPA5;...
Cushing syndrome -1.62 3.82e-2 125/155 (80.65%) APC;CACNA1D;FZD2;...
Rap1 signaling pathway -1.63 3.85e-2 184/210 (87.62%) PDGFRB;ITGB1;VEGFA;...
Circadian entrainment -1.66 2.95e-2 85/97 (87.63%) GRIA3;CALML5;GUCY1B1;...
Axon guidance -1.67 2.85e-2 151/182 (82.97%) PPP3R1;PPP3CA;RHOA;...
Thyroid hormone signaling pathway -1.68 2.65e-2 112/121 (92.56%) RHEB;RAF1;NCOA1;...
Adrenergic signaling in cardiomyocytes -1.70 2.38e-2 130/150 (86.67%) CREB3L1;ATP1B3;PPP2R3C;...
Long-term depression -1.72 1.89e-2 55/60 (91.67%) GRIA3;GNA12;GUCY1B1;...
Vascular smooth muscle contraction -1.74 1.55e-2 113/133 (84.96%) CALML5;GNA12;GUCY1B1;...
Insulin secretion -1.77 1.01e-2 75/86 (87.21%) CREB3L1;KCNN4;ATP1B3;...
Aldosterone synthesis and secretion -1.78 9.52e-3 85/98 (86.73%) CREB3L1;ATP1B3;SCARB1;...
GnRH secretion -1.81 6.93e-3 60/64 (93.75%) RAF1;TRPC4;GABBR2;...
GABAergic synapse -1.81 7.36e-3 76/89 (85.39%) ADCY7;GABRA5;GLUL;...
Dopaminergic synapse -1.81 7.85e-3 115/132 (87.12%) CREB3L1;GNAL;PPP2R3C;...
Vasopressin-regulated water reabsorption -1.83 6.88e-3 40/44 (90.91%) PRKACB;DYNC1I2;AQP4;...
Protein processing in endoplasmic reticulum -1.83 7.41e-3 127/171 (74.27%) DNAJA1;GANAB;HYOU1;...
Regulation of actin cytoskeleton -1.85 6.24e-3 185/218 (84.86%) SOS1;ABI2;ARPC5;...
Gap junction -1.85 5.84e-3 72/88 (81.82%) GNAI3;PRKACB;TJP1;...
Adherens junction -1.85 6.42e-3 63/71 (88.73%) TGFBR2;PTPRB;SSX2IP;...
Platelet activation -1.87 4.76e-3 106/124 (85.48%) ITGB1;ITGA2;ARHGAP35;...
Melanogenesis -1.94 1.34e-3 74/101 (73.27%) CALML5;ADCY7;RAF1;...
Cortisol synthesis and secretion -1.98 0.00e+0 58/65 (89.23%) AGT;KCNK2;PRKACB;...
Cholinergic synapse -1.99 0.00e+0 99/113 (87.61%) BCL2;GNAI3;PRKACB;...
Long-term potentiation -1.99 0.00e+0 61/67 (91.04%) CALML5;BRAF;PPP3R1;...
Glutamatergic synapse -2.01 0.00e+0 97/114 (85.09%) GRIA3;SHANK2;ADCY7;...
Focal adhesion -2.10 0.00e+0 180/201 (89.55%) PDGFRB;ITGB1;VEGFA;...
Oocyte meiosis -2.15 0.00e+0 90/129 (69.77%) ESPL1;CALML5;ADCY7;...
Progesterone-mediated oocyte maturation -2.16 0.00e+0 75/100 (75%) ADCY7;BRAF;RAF1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 0.37uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 12uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 0.37uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 0.37uM 6H
MDST8 CVCL_1400 Homo sapiens 0.37uM 6H
NCI-H508 CVCL_1561 Homo sapiens 0.37uM 6H
SNU-1040 CVCL_5001 Homo sapiens 0.37uM 6H
SNU-C4 CVCL_5008 Homo sapiens 0.37uM 6H
SNU-C5 CVCL_5009 Homo sapiens 0.37uM 6H
SW480 CVCL_0546 Homo sapiens 0.37uM 6H
SW620 CVCL_0547 Homo sapiens 0.37uM 6H
SW948 CVCL_0550 Homo sapiens 0.37uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 0.37uM 6H
HT115 CVCL_1294 Homo sapiens 0.37uM 6H
RKO CVCL_0504 Homo sapiens 0.37uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.37uM 6H
SNG-M CVCL_1707 Homo sapiens 0.37uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 0.37uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.37uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 12uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 0.37uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 0.37uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.37uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 0.37uM 6H
T3M-10 CVCL_1729 Homo sapiens 0.37uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 0.37uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 0.37uM 6H
HCC515 CVCL_5134 Homo sapiens 0.37uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.37uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 0.37uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 0.37uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 0.37uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 0.37uM 6H
OV7 CVCL_1623 Homo sapiens 0.37uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 0.37uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 0.37uM 6H
RMUG-S CVCL_1666 Homo sapiens 0.37uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 0.37uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 0.37uM 6H
PL-21 CVCL_2161 Homo sapiens 0.37uM 6H
SKM-1 CVCL_0010 Homo sapiens 0.37uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.37uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.37uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 0.37uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 0.37uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.37uM 6H